Sarepta Therapeutics is an American medical research company dedicated to the discovery and development of precisely effective gene therapeutics for the treatment of rare neuromuscular diseases.
Key failure to deliver metrics for Sarepta Therapeutics
:
Last SEC data release: 2025-02-28
Last 15 days FTD volume: โฌ0.06 M
Last 3 months FTD volume: โฌ2.35 M
Last year FTD volume: โฌ2.35 M
A Failure to deliver also known as fails-to-deliver or FTD occurs when a buyer or seller is unable to meet his trading obligations. FTDs for US listed companies are reported to the SEC and published twice a month. Therefore there is a certain delay between the reporting and the publishing of the data.
Failures to deliver for Sarepta Therapeutics
(SRPT) - 3 months history
Number of shares, 3 months chart
Biweekly Failures to deliver volume for Sarepta Therapeutics
(SRPT) - since 2013
Volume in USD (price x number of shares), data since 2013
Sarepta Therapeutics
(SRPT) Failure to deliver volume, Year over Year
Year
Volume (Price x Shares)
Change
2025
โฌ0.48 M
-98.83%
2024
โฌ41.97 M
24.73%
2023
โฌ33.65 M
66.59%
2022
โฌ20.2 M
-64.04%
2021
โฌ56.17 M
-40.62%
2020
โฌ94.6 M
-66.33%
2019
โฌ0.28 B
16.72%
2018
โฌ0.24 B
253.79%
2017
โฌ68.05 M
-40.35%
2016
โฌ0.11 B
190.97%
2015
โฌ39.21 M
-69.48%
2014
โฌ0.12 B
79.12%
2013
โฌ71.71 M
FTD volume in the last 3 months for similar companies or competitors